Kwong Ava, Ho Cecilia Yuen Sze, Au Chun Hang, Tey Sze Keong, Ma Edmond Shiu Kwan
Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong SAR, China.
Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong SAR, China.
J Pers Med. 2024 Aug 16;14(8):866. doi: 10.3390/jpm14080866.
RAD51C and RAD51D are crucial in homologous recombination (HR) DNA repair. The prevalence of the RAD51C and RAD51D mutations in breast cancer varies across ethnic groups. Associations of RAD51C and RAD51D germline pathogenic variants (GPVs) with breast and ovarian cancer predisposition have been recently reported and are of interest.
We performed multi-gene panel sequencing to study the prevalence of RAD51C and RAD51D germline mutations among 3728 patients with hereditary breast and/or ovarian cancer (HBOC).
We identified 18 pathogenic RAD51C and RAD51D mutation carriers, with a mutation frequency of 0.13% (5/3728) and 0.35% (13/3728), respectively. The most common recurrent mutation was RAD51D c.270_271dupTA; p.(Lys91Ilefs*13), with a mutation frequency of 0.30% (11/3728), which was also commonly identified in Asians. Only four out of six cases (66.7%) of this common mutation tested positive for homologous recombination deficiency (HRD).
Taking the family studies in our registry and tumor molecular pathology together, we concluded that this relatively common RAD51D variant showed incomplete penetrance in our local Chinese community. Personalized genetic counseling emphasizing family history for families with this variant, as suggested at the UK Cancer Genetics Group (UKCGG) Consensus meeting, would also be appropriate in Chinese families.
RAD51C和RAD51D在同源重组(HR)DNA修复中至关重要。乳腺癌中RAD51C和RAD51D突变的发生率在不同种族群体中有所不同。最近有报道称RAD51C和RAD51D种系致病变异(GPV)与乳腺癌和卵巢癌易感性有关,这引起了人们的关注。
我们进行了多基因panel测序,以研究3728例遗传性乳腺癌和/或卵巢癌(HBOC)患者中RAD51C和RAD51D种系突变的发生率。
我们鉴定出18例致病性RAD51C和RAD51D突变携带者,突变频率分别为0.13%(5/3728)和0.35%(13/3728)。最常见的复发性突变是RAD51D c.270_271dupTA;p.(Lys91Ilefs*13),突变频率为0.30%(11/3728),在亚洲人中也很常见。在这一常见突变的6例病例中,只有4例(66.7%)检测出同源重组缺陷(HRD)呈阳性。
结合我们登记处的家族研究和肿瘤分子病理学,我们得出结论,这种相对常见的RAD51D变异在我们当地的中国人群体中表现出不完全外显率。正如英国癌症遗传学小组(UKCGG)共识会议所建议的,对携带这种变异的家庭强调家族史的个性化遗传咨询在中国家庭中也是合适的。